In a move that captures the attention of international corporations and law firms, the United States’ Food and Drug Administration (FDA) postponed the enforcement date for organizations to conform with the Drug Supply Chain Security Act (DSCSA). Originally slated for November 27, 2023, the enforcement deadline affects drug and device manufacturers, wholesale distributors, dispensers, and repackagers – collectively termed “Trading Partners”.
According to a guidance document issued on August 25th, these Trading Partners now have more time to align their operations with the enhanced drug distribution security requirements. The DSCSA aims to enable the FDA to safeguard the legitimacy of drugs in the U.S. market, thereby preventing the circulation of falsified medicines.
Despite this respite, Trading Partners are encouraged to continue to prepare for the DSCSA’s new requirements in order to minimize disruption when the deadline eventually arrives. The extension is simply meant to provide adequate time for the industry to adjust to the new regulations, not to provide an opportunity for relaxation around this pivotal health concern.
This information was released by Quarles & Brady LLP on JDSupra, a source of legal intelligence. Trading Partners should invest this extra time strategically to ensure they’re set up for full compliance when the deadline finally arrives. This is not just about legal compliance, but also about playing a role in securing the drug supply chain to protect public health.